Literature DB >> 30356128

Drug targeting in Acanthamoeba keratitis: rational of using drugs that are already approved for ocular use in non-keratitis indications.

Abdul Mannan Baig1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30356128      PMCID： PMC6460712          DOI： 10.1038/s41433-018-0245-6

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

Review 1.  Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment.

Authors:  D V Seal
Journal:  Eye (Lond)       Date:  2003-11       Impact factor: 3.775

2.  Successful treatment of Acanthamoeba keratitis without anti-amoebic agents.

Authors:  Archimedes L D Agahan; Ruben B S Lim; Mario J Valenton
Journal:  Ann Acad Med Singapore       Date:  2009-02       Impact factor: 2.473

3.  Recommendations for the management of Acanthamoeba keratitis.

Authors:  Abdul Mannan Baig; Hareem Zuberi; Naveed Ahmed Khan
Journal:  J Med Microbiol       Date:  2014-02-07       Impact factor: 2.472

4.  Evidence of a M1-muscarinic GPCR homolog in unicellular eukaryotes: featuring Acanthamoeba spp bioinformatics 3D-modelling and experimentations.

Authors:  Abdul Mannan Baig; H R Ahmad
Journal:  J Recept Signal Transduct Res       Date:  2016-09-07       Impact factor: 2.092

5.  Toxic effects of selected proprietary dry eye drops on Acanthamoeba.

Authors:  Ines Sifaoui; María Reyes-Batlle; Atteneri López-Arencibia; Olfa Chiboub; Javier Rodríguez-Martín; Pedro Rocha-Cabrera; Basilio Valladares; José E Piñero; Jacob Lorenzo-Morales
Journal:  Sci Rep       Date:  2018-06-04       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.